NASH-focused Akero Therapeutics extends its runway by another year with Pfizer’s help

Two years ago, Akero Therapeutics laid out what one analyst called the “best-in-class NASH data so far” in a field littered with trial failures and ambiguous readouts. Following those interim Phase II results, Akero embarked on a larger Phase II trial that is supposed to report out later this year.

...

Click to view original post